AbCellera Biologics Inc. Research and Development Expense
AbCellera Biologics Inc. (ABCL) reported Research and Development Expense of $45.99 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-05
- AbCellera Biologics Inc. research and development expense for the quarter ending 2026-06-30 was $45.99M, a 17.27% increase year-over-year.
- AbCellera Biologics Inc. research and development expense for the quarter ending 2026-03-31 was $46.66M, a 9.80% increase year-over-year.
- AbCellera Biologics Inc. research and development expense for the quarter ending 2025-12-31 was $50.09M, a 8.72% increase year-over-year.
- AbCellera Biologics Inc. research and development expense for the quarter ending 2025-09-30 was $55.03M, a 34.32% increase year-over-year.
- AbCellera Biologics Inc. research and development expense for fiscal 2025 was $186.83M, a 11.70% increase from fiscal 2024.
- AbCellera Biologics Inc. research and development expense for fiscal 2024 was $167.26M, a 4.78% decline from fiscal 2023.
- AbCellera Biologics Inc. research and development expense for fiscal 2023 was $175.66M, a 62.83% increase from fiscal 2022.
- AbCellera Biologics Inc. research and development expense for fiscal 2022 was $107.88M, a 73.82% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $45.99M 10-Q · filed 2026-08-05 | $92.65M 10-Q · filed 2026-08-05 | $142.74M derived: sum of 3 quarters · filed 2026-08-05 | $197.77M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $46.66M 10-Q · filed 2026-05-11 | $96.75M derived: sum of 2 quarters · filed 2026-05-11 | $151.78M derived: sum of 3 quarters · filed 2026-05-11 | $191.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $50.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $105.12M derived: sum of 2 quarters · filed 2026-02-24 | $144.33M derived: sum of 3 quarters · filed 2026-08-05 | $186.83M 10-K · filed 2026-02-24 |
| 2025-09-30 | $55.03M 10-Q · filed 2025-11-06 | $94.24M derived: sum of 2 quarters · filed 2026-08-05 | $136.74M 10-Q · filed 2025-11-06 | $182.81M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $39.21M 10-Q · filed 2026-08-05 | $81.71M 10-Q · filed 2026-08-05 | $127.78M derived: sum of 3 quarters · filed 2026-08-05 | $168.75M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $42.50M 10-Q · filed 2026-05-11 | $88.57M derived: sum of 2 quarters · filed 2026-05-11 | $129.54M derived: sum of 3 quarters · filed 2026-05-11 | $170.47M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $46.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $87.05M derived: sum of 2 quarters · filed 2026-02-24 | $127.97M derived: sum of 3 quarters · filed 2026-02-24 | $167.26M 10-K · filed 2026-02-24 |
| 2024-09-30 | $40.97M 10-Q · filed 2025-11-06 | $81.90M derived: sum of 2 quarters · filed 2025-11-06 | $121.18M 10-Q · filed 2025-11-06 | $169.81M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $40.93M 10-Q · filed 2025-08-07 | $80.21M 10-Q · filed 2025-08-07 | $128.84M derived: sum of 3 quarters · filed 2026-02-24 | $166.75M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $39.29M 10-Q · filed 2025-05-08 | $87.91M derived: sum of 2 quarters · filed 2026-02-24 | $125.83M derived: sum of 3 quarters · filed 2026-02-24 | $162.30M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $48.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $86.54M derived: sum of 2 quarters · filed 2026-02-24 | $123.01M derived: sum of 3 quarters · filed 2026-02-24 | $175.66M 10-K · filed 2026-02-24 |
| 2023-09-30 | $37.92M 10-Q · filed 2024-11-04 | $74.39M derived: sum of 2 quarters · filed 2024-11-04 | $127.04M 10-Q · filed 2024-11-04 | $155.28M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $36.47M 10-Q · filed 2024-08-06 | $89.12M 10-Q · filed 2024-08-06 | $117.36M derived: sum of 3 quarters · filed 2025-02-27 | $143.95M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $52.65M 10-Q · filed 2024-05-07 | $80.89M derived: sum of 2 quarters · filed 2025-02-27 | $107.47M derived: sum of 3 quarters · filed 2025-02-27 | $134.16M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $28.25M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $54.83M derived: sum of 2 quarters · filed 2025-02-27 | $81.51M derived: sum of 3 quarters · filed 2025-02-27 | $107.88M 10-K · filed 2025-02-27 |
| 2022-09-30 | $26.58M 10-Q · filed 2023-11-02 | $53.27M derived: sum of 2 quarters · filed 2023-11-02 | $79.63M 10-Q · filed 2023-11-02 | $96.84M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $26.68M 10-Q · filed 2023-08-03 | $53.05M 10-Q · filed 2023-08-03 | $70.26M derived: sum of 3 quarters · filed 2024-02-20 | $87.71M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | $26.37M 10-Q · filed 2023-05-04 | $43.58M derived: sum of 2 quarters · filed 2024-02-20 | $61.02M derived: sum of 3 quarters · filed 2024-02-20 | $76.07M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $17.21M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $34.66M derived: sum of 2 quarters · filed 2024-02-20 | $49.70M derived: sum of 3 quarters · filed 2024-02-20 | $62.06M 10-K · filed 2024-02-20 |
| 2021-09-30 | $17.45M 10-Q · filed 2022-11-08 | $32.50M derived: sum of 2 quarters · filed 2022-11-08 | $44.85M 10-Q · filed 2022-11-08 | $53.48M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | $15.05M 10-Q · filed 2022-08-09 | $27.40M 10-Q · filed 2022-08-09 | $36.03M derived: sum of 3 quarters · filed 2023-02-21 | $43.53M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-03-31 | $12.35M 10-Q · filed 2022-05-10 | $20.99M derived: sum of 2 quarters · filed 2023-02-21 | $28.48M derived: sum of 3 quarters · filed 2023-02-21 | $37.63M derived: sum of 4 quarters · filed 2023-02-21 |
| 2020-12-31 | $8.64M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $16.13M derived: sum of 2 quarters · filed 2023-02-21 | $25.27M derived: sum of 3 quarters · filed 2023-02-21 | $29.39M 10-K · filed 2023-02-21 |
| 2020-09-30 | $7.50M 10-Q · filed 2021-11-10 | $16.64M derived: sum of 2 quarters · filed 2021-11-10 | $20.76M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $9.14M 10-Q · filed 2021-08-13 | $13.26M 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | $4.12M 10-Q · filed 2021-05-14 | |||
| 2019-12-31 | $10.11M 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |